

Twitter Thread by Condorito



Condorito

@Arquitect3



1/ THREAD: Long ImmunoPrecise Antibodies (IPA- Nasdaq)

\$IPA is my largest holding since mid-2020, I haven't sold a share

This thread is just the peak of the iceberg as IPA has made such progress that highlighting all on a thread isn't possible, apologize for lots of omissions

2/ IPA is composed of 2 businesses:

The CRO (Contract Research Organization) and Talem Therapeutics.

Both the CRO and Talem are on fire. The CRO is growing at +50% with GM of 60% and Talem (drug discovery company) has several programs with some about to start Phase 1.

3/ Current Market CAP 315MCAD /250M USD

SO: ~16M


Rev run rate ~20M CAD- Growth 50%

Cash: 16M CAD

4/ Let's start with the CRO. In the antibodies space, IPA is the ONLY CRO that offers a complete end-to-end service from concept to clinical trials

5/CRO's revenues are growing at 50%, with 60% gross margins (the CRO industry has ~12% margins), IPA has more than 70% of the top 20 pharma as clients, more than 500 total clients, EBITDA positive, \$16m in cash and run rate revenues of ~\$20M for this fiscal year

YoY Financials



6/ IPA's CRO faced an evolution with the arrival of Dr Bath as CEO where it transitioned from the low-value diagnostic market to the high-value therapeutic market, IPA managed to do that with two transformative acquisitions: UPE and Modiquest and the incorporation of a Top team


Roadmap to Success



7/ IPA CRO is able to have ~60% margins as it is the only CRO in the antibodies space that supports pre-clinical drug discovery from concept to IND enabling studies, so IPA's clients don't need to leave IPA until their programs are well advanced & avoid the transport of materials

8/ As of today the CRO managed to onboard 70% of the top 20 pharma companies as clients (and growing) and has already had 2 quarters of Positive (adjusted) EBITDA. Clients start with small projects and with experience give larger projects to IPA (more projects with higher value)

9) How big is the antibody therapeutics market, see below. I expect IPA to capture growth rates well above the industry ones. The CEO started at IPA by bringing a top-class team, developed the strategy of the CRO and launched Talem, which is IPA's drug discovery company



Therapeutic Antibodies

Market Growth and Convergence

- > **Explosive market growth for human therapeutic antibodies**
 - > Therapeutic market expected to grow to \$300B USD by 2025
 - > *In vitro* diagnostics market projected to reach over \$133B USD by 2027
- > **7 of the top 10 best-selling drugs in 2019**
- > **Drivers of CRO growth**
 - > Increased reliance from industry
 - > Robust biopharmaceutical funding
 - > Accelerated drug approval rates
 - > Growing number of antibody clinical trials
 - > Increase in biopharma without internal research capabilities
 - > Emphasis on vendor consolidation
- > **IPA at intersection of two rapidly accelerating markets**
- > **Could market surpass projections?**
 - > Market transformation through innovation and consolidation
 - > Demand in emerging markets

10/ To finalize the CRO, I expect revenues to grow no less than 30% PA (currently at +50%) maintain margins around 60% & operational leverage will be clear as extra growth should go to the bottom line, (unless it is used to fund Talem). The current MC supports the CRO alone

11/ Let me introduce TALEM Therapeutics.

Talem is IPA'S subsidiary focused on the discovery and development of next-generation fully human, monoclonal therapeutic antibodies. Talem is designed to take ownership stakes during the antibody's discovery and development states.

12/Talem was founded in 2019 and an internal pipeline was created. TALEM is disease agnostic and uses the CRO's services at cost.

Talem is the most exciting component of IPA. Programs in the pre-clinical pipeline range from immuno-oncology to COVID-19

13/ I want to show the huge evolution on Talem's pipeline (see both slides below), in only a few months TALEM pipeline moved from 9 programs with only one partner to more than 16 today with several partners and some are about to present pre-clinical trials data, ready to phase 1



14/ It is hard to describe how valuable that pipeline can become, and how impressive it is that Talem's programs have been predominantly funded by the CRO.

I will focus on one now, to show the quality of the company: The COVID Program

15/ IPA's COVID program started in Jan 2020 with the aim to find a therapeutic that is efficacious for the current strains (of the time) & future viral mutations. Remember Regeneron antibody treatment with 1 antibody? IPA is in pre-clinical trials with a cocktail of 4 antibodies

Leveraging Our Strengths to Combat SARS-CoV-2

Talem Therapeutics has been actively involved in COVID-19 research since January 2020. Monoclonal antibodies were derived from several animal species, including transgenic Omnicats® animals, rabbits, llama, and human, to access a broad epitope coverage. We exploit multiple antibody formats, valencies, and sizes to select antibodies against multiple/rare epitopes. In a multi-national effort, involving our scientists in North America and Europe, Talem has now developed a rich and diverse discovery portfolio of SARS-CoV-2 candidate antibodies yielding epitope and functional diversity.



16/ This cocktail is called the Polytope, I encourage to read the explanation in the below link to start understanding the science. Bottom line, if the Polytope works it would be efficacious with future mutations, pre-clinical trials about to be released

The Polytope™ Advantage

- Leverages the complementary strengths of multiple antibody discovery platforms to generate diverse panels of antibodies.
- Designed to be effective against more than one virus variant and to retain efficacy as the virus mutates and evolves, using rationally combined antibody cocktails.
- Provides numerous data points on thousands of antibodies, enabling data correlation and analysis to address future SARS sequences, including new strains and seasonal variations.
- Provides the foundational information for the COVID-19 therapy.
- Platform suitable for other emerging pathogens

Our unique **advantage** is how we source the antibodies, in parallel, using multiple species (human, llama, Omnicrits®, or rabbits), formats (scFv from human, VHH from llama, or full-length IgG from rat or rabbit), using various antibody discovery methods *in vivo* and *in vitro* (B cell, hybridoma and phage display), thereby leveraging the **unique strengths** inherent to each platform and compensating for their blind spots, since no single platform is universally the best approach for a given target or purpose. **Format and Formulation:**

- We leverage complementary strengths of multiple antibody discovery platforms because no one platform is universally the best.
- The use of multiple species and multiple antibody formats covers blind-spots inherent to each individual discovery platform.
- Lead clones are combined into cocktails to unlock synergistic effects.
- Modular format allows for bispecific formation to leverage favorable functional/ binding properties into fewer leads for manufacture.
- Large antibody library provides many potential combinations to address emerging mutations or multiple indications.

17/ IPA's is also engaged in vaccines (currently in trials-see below) & in the last 5 months has initiated various partnerships, collaborations, etc, all of which are highlighted on the below slide:

Please see for your self the quality of the partners IPA has engaged since SEP



Recent Company Highlights

- > **Partnered on Launch of SARS-CoV-2 Nanomedicine Therapy Program:** December 30, 2020 IPA announced joining the COVABELP consortium, who received EUREKA program funding through Health Holland, to develop a SARS-CoV-2-specific therapeutic nanomedicine that is administered via nasal inhalation and is also intended for vaccination and *in vitro* diagnostics.
- > **Announced the Commencement of Trading on Nasdaq Stock Exchange:** December 23, 2020 – IPA announced that its common shares had been approved for listing on the NASDAQ Global Market under the trading ticker symbol "IPA." Trading on the Nasdaq was expected to commence at market open on December 30, 2020.
- > **Selected Lead Formulation for Preclinical PolyTope™ Antibody Cocktail Therapy:** In November 2020, IPA announced the nomination the first anti-SARS-CoV-2 cocktail therapy consisting of four, human, synergistic antibodies for preclinical testing in the well-defined, SARS-CoV-2, Syrian hamster model.
- > **Entered into Technology Partnership with Genmab:** In November 2020, IPA entered into a research agreement with Genmab A/S, to generate novel bispecific antibody combinations using Genmab's proprietary DuoBody® platform and IPA's proprietary antibodies in the field of infectious disease.
- > **Announced Strategic AI Partnership with Mila:** In November 2020, IPA announced a partnership with Mila, a world-renowned artificial intelligence (AI) research institute.
- > **Announced Collaboration with Twist Biosciences for the Creation of Novel, Therapeutic Antibody Products:** In October 2020, IPA announced a collaboration with Twist Biosciences to leverage Twist's silicon DNA platform to enhance its antibody therapeutics and expand its early-stage pipeline.
- > **Initiated Preclinical Trials for SARS-CoV-2 Vaccines in Collaboration with LiteVax:** In September 2020, IPA, in partnership with LiteVax, initiated preclinical trials for a set of vaccine candidates against SARS-CoV-2. The formulations were designed using IPA's extensive data sources and LiteVax's novel adjuvant.
- > **Released Second-Generation B Cell Select™:** In September 2020, IPA Europe announced the release of a second-generation B-Cell platform with technology aimed at accelerating antibody identification and discovery by increasing automation of their selection technology and subsequent single cell cloning.
- > **Announced Multi-Specific Antibody Collaboration with Zymeworks:** In September 2020, IPA announced a research collaboration with Zymeworks to utilize their Azymetric™ and EFECT™ platforms for the development of antibody candidates against COVID-19.
- > **Completed Application Process to Dual Listing on NASDAQ:** In September 2020, IPA announced its application to list on the NASDAQ Global Market ("Nasdaq") exchange and started trading December 30, 2020 under the trading ticker symbol "IPA". NASDAQ is the world's pre-eminent exchange for biotech and pharma companies and will expand the Company's exposure and access to U.S. and international investors.

18/ I have left so much out, and I deliberately made this thread non-scientific, however below I include some sources where you can get a grasp of the science, and they are a must-watch.

1: <https://t.co/evkgcuhW1f>

2: <https://t.co/xellm13wMv>

3: <https://t.co/olpUVw8x1G>

19/ On the last conference the CEO mentioned the 1st commercial sale of internal Talem antibodies and announced material revenue from license deals within the next 2 quarters. This validates Talem in a serious way

20/ The industry is after the next-generation sequencing which is designing cocktails by screening ag libraries the companies build, while not apple to apple IPA can be at some extent compared to Abcellera (ABCL has a transgenic animal, IPA does not) but ABCL is priced 50x IPA

21/ We get Talem's potential relatively for free as the current market cap supports only the CRO. IPA just listed on NASDAQ and remains extremely under the radar, I don't think this will be the case for long, as IPA has hired a top IR firm & eventually institutions will become SH

22/ As usual some programs will not work, but some will and many companies with programs in Phase 1 trials already have multi-billion \$ valuations, it is hard to not see the potential and most importantly the "OPTIONALITY" of IPA

23/ IPA did a prospectus where they can raise up to \$150M, I would like IPA to do a PP in order to bring institutions on board and use that capital either for acquisitions for the CRO or clearly for Talem. With the Nasdaq listing, this makes total sense.

24/ An illustration of what is to come: Yasmina Noubia Abdiche, IPA's Chief Scientific Officer latest patents:

<https://t.co/iAAJWJxbe0>

END/ As mentioned this thread covers only a portion of what \$IPA is, management is outstanding and I am truly excited for IPA's future. DYODD

Find below the latest deck:

<https://t.co/r42pXenMX6>